Conclusion: In an observational study in patients with type 2 diabetes with acute myocardial infarction, it was found that SGTL2 inhibitor treatment was associated with lower rates of first hospitalisation for heart failure and all-cause death. During the one year of follow-up, treatment with SGLT2 inhibitors was associated with a 30% lowered hazard ratio of the primary composite outcome of first hospitalisation for heart failure or all-cause death. This finding was consistent in the sensitivity analyses and among all subgroups.